Citius pharmaceuticals, inc. reports fiscal second quarter 2022 financial results and provides business update

Mino-lok® phase 3 trial expanded to include sites outside the u.s.; trial enrollment expected to be completed by end of 2022 topline results of phase 3 trial in cancer immunotherapy i/ontak consistent with prior formulation; bla submission on track for 2h 2022 $55.8 million in cash and cash equivalents as of march 31, 2022 and no debt cranford, n.j. , may 12, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the second fiscal quarter of 2022 ended march 31, 2022.
CTXR Ratings Summary
CTXR Quant Ranking